Tandem Diabetes Care Inc
(LTS:0M0F)
$
32.8
-0.13 (-0.39%)
Market Cap: 2.17 Bil
Enterprise Value: 2.19 Bil
PE Ratio: 0
PB Ratio: 9.19
GF Score: 76/100 
Tandem Diabetes Care Inc at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023 / 07:45PM GMT
Release Date Price:
$25.76
(-8.63%)
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
All right. Good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with the management team from Tandem Diabetes.
With us, we have John Sheridan, President and CEO; and Leigh Vosseller, Executive Vice President and CFO. In terms of format, it's a fireside chat. If anybody has a question, please raise your hand, come around with the mic. John and Leigh, thanks so much for being here.
Leigh A. Vosseller
Tandem Diabetes Care, Inc. - Executive VP, CFO & Treasurer
Sure.
John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director
Thanks for having us. Nice to be here.
Questions & Answers
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
So let's start off with the GLP-1 since there
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers